| 영문 | extracellular fluid | 한글 | 세포외액 |
|---|---|---|---|
| 설명 | 세포외에 존재하는 모든 체액에 대한 일반명. 사이질액, 혈장, 림프액, 뇌척수액 등을 포함한다. 즉, 능동적인 세포분비에 의해 생기는 액으로 이루어진다. 일정한 세포의 정상적 외환경을 만들어 준다. |
||
| 영문 | serum enzyme | 한글 | 혈청효소 |
|---|---|---|---|
| 설명 | 혈청 내에 포함되어 있는 여러 가지 효소를 일컫는 말이다. |
||
| 영문 | enzyme | 한글 | 효소 |
|---|---|---|---|
| 설명 | 생물체 세포속에서 합성되고, 주로 세포내에서 진행되는 화학반응을 촉매하는 단백질로 시험관내에서도 같은 촉매작용을 한다. 이 효소는 인공적으로 만든 어떤 촉매제보다 그 특이성과 촉매작용이 탁월한 특별한 생체분자이다. 신진대사, 즉 세포내에서 일어나는 물질의 화학적 변환은 효소의 작용에 의해 매우 빠르고 원할하게 이루어진다. 이것은 효소의 촉매 효율이 높은 점과 효소의 기질 특이성 때문이다. 효소반응은 상온, 상압, 최적 pH 등 적절한 조건 아래에서 진행된다. 또 효소의 주체가 단백질이기 때문에 단백질을 변성시키는 열, 강산, 강알칼리, 유기용매 등에 의해 그 작용을 잃는다. 효소는 생체에 널리 분포하며, 복잡하고 다양한 대사반응을 촉매하기 때문에 종류도 많다. 앞서 말한 바와 같이 대부분의 효소는 세포내에 존재하지만, 혈액과 그외의 간질액에 들어 있기도 하고 소화효소류처럼 체외로 분비되는 것도 있다. |
||
| 영문 | enzyme-linked immunoabsorbent assay | 한글 | 효소면역측정법 |
|---|---|---|---|
| 설명 | 효소결합면역흡착제 검정법으로 번역되고 있다. 이 법은 항원(또는 항체)에 알칼리 포스파타아제 또는 페르옥시디아제 등의 산소를 결합시켜 두고 그 산소활성을 지표로 삼아 항원항체반응의 정도를 안 다음 여기에서 항원(또는 항체)의 양을 구하는 것이다. 이 법의 이점으로서 고감도, 조작의 간단함 및 방사선면역측정법처럼 방사성물질을 사용하지 않아도 된다는 점을 들 수 있다. 호르몬이나 면역글로불린의 정량법으로서 응용 되고 있으며 측정용 키트도 시판되고 이있다. |
||
| EC | effective concentration; ejection click; electrochemical; electron capture; embryonal carcinoma; eme... |
|---|---|
| ECM | electronic claims management; embryonic chick muscle; erythema chronicum migrans; experimental cereb... |
| EPS | ear-patella-short stature [syndrome]; elastosis perforans serpiginosa; electrophysiologic study; enz... |
| EIA | electroimmunoassay; enzyme immunoassay; enzyme-linked immunosorbent assay; equine infectious anemia;... |
| PACE | Pacing and Clinical Electrophysiology; paired basic amino acid cleaving enzyme; personalized aerobic... |
| ERK | 1-extracellular signal-regulated kinase |
|---|---|
| AEP | Alkaline Extracellular Protease |
| ECM | Cell-extracellular matrix |
| E | Extracellular |
| EC | Extracellular |
| extracellular enzyme | <enzyme> An enzyme performing its functions outside a cell; e.g., the various digestive enzyme's. Synonym: exoenzyme, lyoenzyme. (05 Mar 2000) |
|---|
| extracellular | Outside a cell or cells. (18 Nov 1997) |
|---|---|
| extracellular fluid | The fluid found outside of the cell or cells and between the cells in a tissue. (09 Oct 1997) |
| extracellular fluid volume | The fraction of body wate rnot in cells; about 25% of body weight. It consists of plasma water (4.5% of body weight), water between cells (interstitial water-lymph, 11.5% of body weight), water in dense bone and connective tissue (7.5% of body weight) and water secretions.See transcellular water, about 1.5% of body weight.. (05 Mar 2000) |
| extracellular matrix | Any material produced by cells and secreted into the surrounding medium, but usually applied to the noncellular portion of animal tissues. The ecm of connective tissue is particularly extensive and the properties of the ecm determine the properties of the tissue. In broad terms there are three major components: fibrous elements particularly collagen, elastin or reticulin), link proteins (e.g. Fibronectin, laminin) and space filling molecules (usually glycosaminoglycans). The matrix may be mineralised to resist compression (as in bone) or dominated by tension resisting fibres (as in tendon). The basal lamina of epithelial cells is another commonly encountered ecm. Although ecm is produced by cells, it has recently become clear that the ecm can influence the behaviour of cells quite markedly, an important factor to consider when growing cells in vitro: removing cells from their normal environment can have far reaching effects. (18 Nov 1997) |
| extracellular matrix proteins | Macromolecular organic compounds that contain carbon, hydrogen, oxygen, nitrogen, and usually, sulfur. These macromolecules (proteins) form an intricate meshwork in which cells are embedded to construct tissues. Variations in the relative types of macromolecules and their organization determine the type of extracellular matrix, each adapted to the functional requirements of the tissue. The two main classes of macromolecules that form the extracellular matrix are: glycosaminoglycans, usually linked to proteins (proteoglycans), and fibrous proteins (e.g., collagen, elastin, fibronectins and laminin). (12 Dec 1998) |
| extracellular space | Interstitial space between cells, occupied by fluid as well as amorphous and fibrous substances. (12 Dec 1998) |
| extracellular toxin | <protein> Toxin released from gram-positive and gram-negative bacteria as opposed to endotoxins that form part of the cell wall. Examples are cholera, pertussis and diphtheria toxins. Usually specific and highly toxic. (18 Nov 1997) |
| Yarrowia lipolytica alkaline extracellular protease | <enzyme> First secreted as precursor Registry number: EC 3.4.21.- Synonym: alkaline extracellular protease, yarrowia lipolytica, yl-ae protease (26 Jun 1999) |
| acetyl-activating enzyme | A ligase that catalyses the reaction of acetate and CoA and ATP to form AMP, pyrophosphate, and acetyl-CoA. A key step in the activation of acetate. Synonym: acetate thiokinase, acetate-CoA ligase, acetyl-activating enzyme, acetyl-CoA synthetase. (05 Mar 2000) |
| acyl-activating enzyme | <enzyme> Fatty acid thiokinase (long-chain), a ligase forming acyl-CoA, AMP, and pyrophosphate from long-chain fatty acids, ATP, and coenzyme A. Activity is independent of phosphatidylcholine Registry number: EC 6.2.1.3 Synonym: acyl-activating enzyme, dodecanoyl-CoA synthetase, fatty acid thiokinase (long chain), acid-coenzyme a ligase, fatty acid-CoA ligase, acyl-CoA synthetase, acyl-CoA ligase, coash ligase, ciprofibroyl-CoA synthetase, pristanoyl-CoA synthetase, palmityl CoA synthetase, palmitoyl CoA synthetase, palmitoyl CoA ligase, fatty acyl-CoA synthetase, very long chain fatty acid acyl-CoA synthetase, vlcfa acyl-CoA synthetase, nafenopin-CoA ligase, palmitoyl-CoA synthase, faa2 gene product, faa2p protein, vlacs enzyme (26 Jun 1999) |
| adaptive enzyme | Inducible enzyme, an enzyme that can be detected in a growing culture of a microorganism, after the addition of a particular substance (inducer) to the culture medium, but was not detectable prior to the addition and can act on the inducer. A prototype is the beta-galactosidase of Escherichia coli, synthesised upon the addition of various galactosides, whether or not these are good substrates. Compare: constitutive enzyme. Synonym: adaptive enzyme. (05 Mar 2000) |
| allosteric enzyme | <biochemistry, chemistry> A regulatory enzyme whose activity is modified by the noncovalent binding of a particular metabolite at a site (the allosteric site) other than the active site. (09 Oct 1997) |
| amino acid activating enzyme | <enzyme> Enzymes catalyzing the formation of a specific aminoacyl-tRNA from an amino acid and adenosine 5'-triphosphate with the concomitant formation of adenosine 5'-monophosphate and pyrophosphate. Synonym: amino acid activating enzyme, aminoacyl-tRNA ligases. (05 Mar 2000) |
| angiotensin-converting enzyme | <enzyme> This hydrolase enzyme cleaves the decapeptide angiotensin I (biologically inactive) to form active angiotensin II by angiotensin-converting enzyme which removes a dipeptide (histidylleucine) from angiotensin I. Angiotensin II causes contraction of vascular smooth muscle and thus raises blood pressure and stimulates aldosterone release from the adrenal glands. Angiotensin is finally broken down by angiotensinases. Elevations in angiotensin converting enzyme are seen sarcoidosis, histoplasmosis, alcoholic cirrhosis, asbestosis, berylliosis, diabetes, Hodgkin's disease, hyperthyroidism, amyloidosis, primary biliary cirrhosis, idiopathic pulmonary fibrosis, pulmonary embolism, scleroderma, silicosis, tuberculosis, Gaucher's disease and leprosy. The normal values are 18 to 67 U/ml over 20 years of age (people under 20 have higher levels). Drugs that inhibit ACE are used to treat hypertension and congestive heart failure. See: angiotensin-converting enzyme inhibitor Acronym: ACE (12 Aug 2000) |
| angiotensin-converting enzyme inhibitor | <pharmacology> A class of drugs used in the treatment of hypertension and heart failure. They exert their haemodynamic effect mainly by inhibiting the renin-angiotensin system and produce a reduction of peripheral arterial resistance. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility. (14 Aug 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|